Vivien E. Prise - Concepedia

Author

Vivien E. Prise

Also Known As

Prise, Vivien E, V E Prise, V Prise, V. E. Prise, V. Prise, V.E Prise, V.E. PRISE, V.E. Prise, VE Prise, Vivien E. Prise

Publications

2.2K

Citations

H-Index

Concepts

All Affiliations

Mount Vernon Hospital University of Sheffield Cancer Research UK Queen's University Belfast University of Ulster

About

Vivien E. Prise is an author at Mount Vernon Hospital specializing in medicine, tumor biology, and tumor microenvironment.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	12	12	1.7K
2	Biomedical Engineering	2	2	303
3	Engineering	1	1	104
4	Health Sciences	1	1	15
5	Biochemistry	1	1	91

Vivien E. Prise

Publications

Citations

H-Index

Page 1

	Year	Citations
Combretastatin A-4, an agent that displays potent and selective toxicity toward tumor vasculature. G. Dark, S A Hill, Vivien E. Prise, PubMed Vascular ShutdownTumor BiologyOncologyCancer Cell BiologySelective Toxicity	1997	624
Combretastatin A-4 phosphate as a tumor vascular-targeting agent: early effects in tumors and normal tissues. G. M. Tozer, Vivien E. Prise, John Wilson, PubMed Quantitative AutoradiographyPathologyTumor BiologyBlood FlowAngiogenesis	1999	324
Mechanisms associated with tumor vascular shut-down induced by combretastatin A-4 phosphate: intravital microscopy and measurement of vascular permeability. Gillian M. Tozer, Vivien E. Prise, John Wilson, PubMed PharmacotherapyBiomedical EngineeringTumor BiologyVascular PermeabilityAngiogenesis	2001	288
Evaluation of the anti‐vascular effects of combretastatin in rodent tumours by dynamic contrast enhanced MRI Ross J. Maxwell, John Wilson, Vivien E. Prise, NMR in Biomedicine EngineeringOncologic ImagingTumour Blood FlowMagnetic Resonance ImagingBlood Flow	2002	104
Blood Vessel Maturation and Response to Vascular-Disrupting Therapy in Single Vascular Endothelial Growth Factor-A Isoform–Producing Tumors Gillian M. Tozer, Simon Akerman, Neil A. Cross, Cancer Research	2008	103
Inhibition of nitric oxide synthase induces a selective reduction in tumor blood flow that is reversible with L-arginine. Gillian M. Tozer, Vivien E. Prise, D J Chaplin PubMed HypertensionCardiovascular PharmacologyPharmacotherapyCardiovascular ToxicityTumor Biology	1997	99
Nitric oxide in biological fluids: analysis of nitrite and nitrate by high-performance ion chromatography Steven A. Everett, Madeleine F. Dennis, G. M. Tozer, Journal of Chromatography A Biological FluidsBiochemistryReactive Nitrogen SpecieNitric OxideBioanalysis	1995	91
The vascular response of tumor and normal tissues in the rat to the vascular targeting agent, combretastatin A-4-phosphate, at clinically relevant doses Vivien E. Prise, Davina J. Honess, Michael R.L. Stratford, International Journal of Oncology Tumor InnervationPathologyPharmacotherapyMetronomic ChemotherapyVascular Targeting Agent	2002	82
Lipoprotein-associated phospholipase A <sub>2</sub> (Lp-PLA <sub>2</sub> ) as a therapeutic target to prevent retinal vasopermeability during diabetes Paul Canning, Bridget-Ann Kenny, Vivien E. Prise, Proceedings of the National Academy of Sciences	2016	66
Estimation of Apparent Tumor Vascular Permeability from Multiphoton Fluorescence Microscopic Images of P22 Rat Sarcomas In Vivo Constantino Carlos Reyes‐Aldasoro, Ian A. Wilson, Vivien E. Prise, Microcirculation	2008	59

Page 1